Share
Brian McNamara
GSK has announced the appointment of Brian McNamara as the CEO Designate for the new Consumer Healthcare company, set to be formed following the proposed demerger of GSK’s Consumer Healthcare business in mid-2022.
This move aligns with GSK’s strategic plan to separate its Consumer Healthcare division through a demerger of at least 80% of GSK’s holding to shareholders, subject to shareholder approval.
The newly independent company is poised to become a global leader in consumer health, with a robust portfolio of brands such as Sensodyne, Voltaren, Panadol, and Centrum. Generating more than £10 billion (US$175billion) in annual sales in 2020, the company is expected to secure a premium listing on the London Stock Exchange.
Brian McNamara’s Leadership Journey
Brian McNamara has been the CEO of GSK Consumer Healthcare since 2015, bringing extensive experience in the over-the-counter (OTC) market. Before joining GSK, he led the OTC division at Novartis, where he was instrumental in creating a thriving Joint Venture between GSK and Novartis. More recently, he played a pivotal role in the partnership between GSK and Pfizer, which established the current Consumer Healthcare business as a world leader.
With his proven track record in driving successful Joint Ventures and his deep industry expertise, McNamara is well-positioned to lead the new Consumer Healthcare Company into its next phase of growth and innovation.
Related posts
